Semaglutide linked to 53% lower risk of death in dialysis patients with diabetes

Key Findings

🧠 Semaglutide may protect against cognitive decline in diabetes

• Mouse studies revealed semaglutide works through a "gut microbiota-bile acid-sphingolipid" pathway to protect the brain from diabetes-related cognitive impairment

• The drug restored beneficial gut bacteria, normalized bile acid profiles, and modulated brain metabolism pathways involved in memory and learning

• Semaglutide appeared to work through both weight-dependent and weight-independent mechanisms in the brain

💪 GLP-1 weight loss comes with concerning muscle loss

• Analysis of 36 studies involving nearly 5 million patients found that people losing weight on GLP-1 drugs lost about 35% of their total weight loss from muscle and other lean tissue

• This exceeded the expected benchmark of 25% muscle loss during weight reduction, with 68% of studies showing higher-than-expected muscle loss

• The pattern was consistent across different measurement methods and drug types, raising questions about long-term metabolic health

🔬 Tirzepatide matches weight-loss surgery effectiveness

• Network analysis of 23 trials with 14,293 participants found tirzepatide (10-15 mg) produced 21.3% total body weight loss—statistically equivalent to sleeve gastrectomy surgery (21.1%)

• Semaglutide achieved 12.7% weight loss while older drugs like orlistat managed only 2.7%

• Among medications, semaglutide had the best safety profile, while tirzepatide matched surgical outcomes without invasive procedures

🫀 GLP-1 drugs show promise for heart failure patients

• Real-world study of 127,021 heart failure patients found those prescribed GLP-1 receptor agonists had 32% lower risk of death and 21% lower risk of heart failure hospitalization

• Among 2,550 matched patients, 1-year mortality was 7.1% for GLP-1 users versus 10.2% for controls

• The benefits appeared consistent despite these patients having reduced heart pumping function, a high-risk condition often excluded from major trials

⚠️ Hair loss emerges as potential GLP-1 side effect

• Systematic review of 24 studies found semaglutide and tirzepatide were most frequently linked to hair loss, particularly at higher obesity-treatment doses

• Females appeared disproportionately affected, with rapid weight loss identified as a potential contributing factor

• The hair loss was mainly androgenetic alopecia and telogen effluvium, with tirzepatide showing the strongest association with stress-related hair loss

🧪 New drug combo avoids GLP-1's stomach problems

• Researchers developed a dual receptor agonist (GIPR:GCGR) that achieved weight loss comparable to existing GLP-1 drugs without targeting the GLP-1 receptor

• In obese mice, the new compound (BWB3054) was over 100-fold less potent at GLP-1 receptors but still normalized body weight effectively

• Three independent methods confirmed obesity could be reversed without GLP-1 activation, potentially avoiding the nausea and vomiting that limit current treatments